期刊文献+

调节血脂治疗的药学监护 被引量:3

Pharmaceutical Care in Medication for Blood Lipid Regulation
下载PDF
导出
摘要 目的 :科学合理地应用调节血脂药,不仅可降低血脂水平,还可减少血管内皮过氧化,稳定或缩小动脉粥样硬化脂质斑块,减少脑卒中和心血管事件的发生,成为一、二级预防心血管病的重要手段,本文对调节血脂治疗中的药学监护要点进行总结。方法:查阅近年来国内、外相关文献,对调节血脂药的研究进展进行分析。结果:联合治疗方案对血脂达标和治疗成败非常关键,使得药学监护十分重要。结论:调节血脂药的合理和安全应用尤为重要,应监护其在治疗中的各种风险和问题,诸如调节血脂药选择、联合用药方案、不良事件(肌毒性、肝毒性)的防范等,并依据血脂类型选择适宜的给药时间。 Objective:The application of lipid regulating agents scientifically and rationally can lower the blood lipid level , reduce the oxidative damage to vascular endothelial cell , stabilize or decrease atherosclerotic plaques and reduce the incidence of stroke and cardiovascular events , which has been regarded as an important means for the primary and secondary prevention . This paper summarized the critical points of pharmaceutical care in regulating blood lipid therapy . Methods:Through reviewing the pertinent medical literatures both at home and abroad published in recent years , a analysis was performed of the research progress on lipid regulating drugs . Results:The combined treatement scheme was crucial to the blood lipid level and the result of treatment , and the great importance of pharmaceutical care was thusly proved . Conclusion: It is of great importance to use lipid regulating drugs in a rational and safety way . Attention should be paid to the risk and problem in the treatment , such as the selection of lipid regulating drugs , combined treatment scheme of medication and the prevention of adverse drug events ( muscle toxicity and hepatotoxicity ) , and a suitable time of administration should be chosen according to the lipid types .
作者 张石革
出处 《中国执业药师》 CAS 2013年第10期5-10,23,共7页 China Licensed Pharmacist
关键词 调节血脂药 他汀类 肌毒性 药学监护 合理用药 Lipid Regulating Agents Statins Muscle Toxicity Pharmaceutical Care Rational Drug Use
  • 相关文献

参考文献18

  • 1Large V,Peroni O ,Letexier D,et al.Metabolism of lipids in hu- man white adipocyte[J].Diabetes Metab, 2004,30 (4) : 299-309.
  • 2孙忠实.药物基因组学与抗血小板药的个体化使用[J].中国医院用药评价与分析,2011,11(10):866-867. 被引量:4
  • 3Nicholls S J, Ballantyne CM, Barter P J, et al. Effect of two inten- sive statin regimens on progression of coronary disease[J]. N Engl J Med,2011 ,365(22) :2078-2087.
  • 4Molander L,Lovheim H,Norrnan T,et al.Lower systolic blood pressure is associated with greater mortality in people aged 85 and older[J].J Am Geriatr Soc, 2008,56 (10) :1853-1859.
  • 5Heart Protection Study Collaborative Group, Bulbulia R, Bowman L. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20536 high-riskindividuals : a randomised controlled trial [J]. Lancet, 2011,378 (9808) :2013-2020.
  • 6Waters DD, Ho JE, DeMicco DA, et al.Predictors of new-onset di- abetes in patients treated with atorvastatin results from 3 large ran- domized clinical trials [J]. J Am Coil Cardiol,2011,57 (14): 1535-1545.
  • 7Perk J, De Backer G, Gohlke H, et al.European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Pre- vention in Clinical Practice (constituted by representatives of nine societies and by invited experts) [J].Eur Heart J, 2012,33 ( 13 ) : 1635-1701.
  • 8Baigent C,Keech A, Kearney PM,et al.Effieaey and safety of cholesterol-lowering treatment : prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J]. Lancet, 2005,366 (9493) : 1267-1278.
  • 9李大魁,张石革.国家执业药师资格考试应试指南--药学综合知识与技能[M].北京:中国医药科技出版社,2011:136-137.
  • 10Stein EA.Managing dyslipidemia in the high-risk patient[J]. Am J Cardiol, 2002,89 (5A) : 50C-57C.

二级参考文献25

  • 1Syrbe G, Redlich H, Weidlich B, et al. Individual dosing of ASA prophylaxis by controlling platelet aggregation [J]. Clin Appl Thromb Hemost,2001,7( 3 ) :209.
  • 2Sobol AB, Watala C. The role of platelets in diabetesrelated vascular complications [ J ]. Diabetes Res Clin Pract,2000,50( 1 ) :1.
  • 3Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study [ J ]. BMJ, 2011,342 : d2690.
  • 4Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids [ J ]. Curr Opin Lipidol,2012,23 (4) : 345-352.
  • 5Ekstedt M, Franzen LE, Mathiesen UL, et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes : a histopathological follow-up study [ J ]. J Hepatol,2007,47 ( 1 ) : 135-141.
  • 6Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo- controlled, multicenter tria [ J ]. Hepatology, 2007,46 (5) :1453-1463.
  • 7Abel T, Feher J, Dinya E, et al. Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease [ J]. Orv Hetil,2009 ,150( 21 ) :989-993.
  • 8Park H, Shima T, Yamaguchi K, et al. Efficacy of long- term ezetimibe therapy in patients with nonalcoholic fatty liver disease [ J ]. J Gastroenterol, 2011, 46 ( 1 ) : 101- 107.
  • 9Dima A, Marinescu AG, Dima AC. Non-alcoholic liver disease and the statins treatment[ J]. Rom J Intern Med, 2012,50( 1 ) :19-25.
  • 10Tandra S, Vuppalanchi R. Use of statins in patients with liver disease [ J ]. Curr Treat Options Cardiovasc Med, 2009,11 (4) :272-278.

共引文献8

同被引文献16

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部